##1. Characteristics of Pancreatic Cancer as a “Cold Tumor” and Limitations of Single-Antigen Vaccines Pancreatic cancer is a prototypical “cold tumor” in which the tumor microenvironment (TME) is highly desmoplastic and impedes immune-cell infiltration. Although mRNA vaccine development has been attempted, the pronounced genetic heterogeneity of pancreatic cancer makes it difficult for a single antigen to fully block tumor immune evasion. Moreover, technical bottlenecks have hampered the identification of antigens that are both low in immunogenicity and uniquely expressed on cancer cells.

##2. Multidimensional Omics Screening: Integration of Tumor Specificity and Immunogenic Cell-Death Pathways The research team constructed a systematic screening pipeline that combined extensive public databases with experimental validation. Beyond simply selecting highly expressed genes, the pipeline evaluated whether candidate antigens could promote antigen-presenting cell (APC) infiltration and whether they were linked to ferroptosis or pyroptosis pathways that robustly stimulate immune responses during cell death. This approach yielded 16 elite antigen candidates capable of simultaneously suppressing tumor growth and actively awakening the immune system.

##3. ADAM9·PAK2 and SCP-1·GAGE: Functional Growth Suppression and Synergy of Cancer-Testis Antigens Among the identified candidates, ADAM9 and PAK2 were confirmed as genes directly involved in tumor proliferation, invasion, and immune regulation; targeting them is expected to deliver both immune attack and direct disruption of tumor survival mechanisms. In contrast, SCP-1 and GAGE are cancer-testis antigens (CTAs) that are absent from normal tissues (except testis) and expressed exclusively in cancer cells, providing an optimal “shield‑piercing” effect that minimizes off‑target toxicity while eliciting strong immunogenicity.

##4. Conversion to a “Hot Tumor” via a Multi-Antigen Cocktail The significance of this work lies in providing a concrete list that enables a paradigm shift from single-target to multi-antigen cocktail vaccination for pancreatic cancer. An mRNA vaccine comprising the 16 candidates can prevent escape driven by tumor mutation, remodel the cold pancreatic TME into a “hot tumor,” and maximize synergy with existing immune-checkpoint inhibitors. This represents a critical technical milestone that makes precision vaccine design tailored to each patient’s antigenic profile feasible.